Global R&D Pipeline
My Favorite
Hot Targets:
CD8
Back
Total number of drugs
82
Phase II and later clinical stages
4.9%
Involving companies
77
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PET immuno-oncology imaging agent (Indi Molecular/GE) | PET immuno-oncology imaging agent (Indi Molecular/GE) | Biological products | Immune System Diseases | CD8 modulators | GE Healthcare, Inc. Indi Molecular, Inc. | Indi Molecular, Inc. GE Healthcare, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | PET immuno-oncology imaging agent (Indi Molecular/GE) | - | - | detail > | |
| CD8-Treg targeted IL-15 Program(Mozart Therapeutics) | CD8-Treg targeted IL-15 Program(Mozart Therapeutics) | Fusion protein | Immune System Diseases | CD8 inhibitors IL-15 modulators | Mozart Therapeutics, Inc. | Mozart Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CD8-Treg targeted IL-15 Program(Mozart Therapeutics) | - | - | detail > | |
| CD8sp_CD28z STEAP1 CAR T | CD8sp_CD28z STEAP1 CAR T | CAR-T | Neoplasms Urogenital Diseases | CD28 agonists CD8 stimulants STEAP1 inhibitors | Oslo universitetssykehus HF | Oslo universitetssykehus HF | Preclinical | - | - | - | - | - | - | - | - | - | CD8sp_CD28z STEAP1 CAR T | - | - | detail > | |
| IL13-CD8TM-28.BB.ζ CAR-T(Shijitan hospital) | IL13-CD8TM-28.BB.ζ CAR-T(Shijitan hospital) | CAR-T | Neoplasms Nervous System Diseases Other Diseases | CD8 inhibitors IL-13Rα2 inhibitors | 首都医科大学附属北京世纪坛医院 | 首都医科大学附属北京世纪坛医院 | Preclinical | Preclinical | - | - | - | - | - | - | - | - | IL13-CD8TM-28.BB.ζ CAR-T(Shijitan hospital) | - | - | detail > | |
| Anti-ROR1/CD3/CD8 trispecific antibody(MacroGenics) | Anti-ROR1/CD3/CD8 trispecific antibody(MacroGenics) | Trispecific antibody | Neoplasms | CD3 stimulants CD8 inhibitors ROR1 antagonists | MacroGenics, Inc. | MacroGenics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Anti-ROR1/CD3/CD8 trispecific antibody(MacroGenics) | - | - | detail > | |
| CD8-L829-tLNP | CD8-L829-tLNP | mRNA | Neoplasms | CD8 inhibitors | Capstan Therapeutics, Inc. | Capstan Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CD8-L829-tLNP | - | - | detail > | |
| Arenavirus vector based vaccine | Arenavirus vector based vaccine | Recombinant vector vaccine Prophylactic vaccine | Neoplasms | CD8 stimulants KRAS G12C inhibitors KRAS G12D inhibitors KRAS G12R inhibitors KRAS G12V inhibitors KRAS G13D inhibitors | HOOKIPA Pharma, Inc. | HOOKIPA Pharma, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | Arenavirus vector based vaccine | - | - | detail > | |
| SG293 | SG293 | in vivo CAR-T therapy | Immune System Diseases Hemic and Lymphatic Diseases | CD19 modulators CD8 modulators | Sana Biotechnology, Inc. | Sana Biotechnology, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | SG293 | - | - | detail > | |
| mRNA-LNP Vaccine(Tsinghua University) | mRNA-LNP Vaccine(Tsinghua University) | Therapeutic vaccine mRNA vaccine | Neoplasms | CD8 modulators | Tsinghua University CHANGPING LABORATORY | Tsinghua University CHANGPING LABORATORY | Preclinical | Preclinical | - | - | - | - | - | - | - | - | mRNA-LNP Vaccine(Tsinghua University) | - | - | detail > | |
| [89Zr]-REGN-5054 | [89Zr]-REGN-5054 | Radiolabeled antibody Diagnostic radiopharmaceuticals | Neoplasms | CD8 modulators | Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. | Preclinical | - | - | - | - | - | - | DFO | 89 Zr | - | [89Zr]-REGN-5054 | - | - | detail > |
Total 82 data
1
2
3
4
5
6
7
8
9
